- LAIR1 suppresses phagocytosis via SHP2/USP22-mediated MYH9 degradation in glioma-associated microglia/macrophages to drive immunosuppression. [Journal Article]Br J Cancer. 2026 Oct 08. [Online ahead of print]BJ
- CONCLUSIONS: LAIR1 is a critical phagocytosis suppressor in GAMs, driving glioma immunosuppression. Targeting LAIR1 represents a promising strategy to restore anti-tumour immunity.
- Publisher Full Text (DOI)
- Trends in incidence and prevalence of patients living long-term with de novo metastatic incurable cancer: a retrospective cohort study. [Journal Article]
- CONCLUSIONS: Substantial increases in the incidence and prevalence were identified, reflecting a shift toward prolonged survival within the incurable cancer population. Greater awareness and research are needed to inform care for this emerging group.
- Publisher Full Text (DOI)
- Integrated spatial and single-cell transcriptomics uncover IFI6[+] regulatory T-cells and SPP1[+] macrophages immunosuppressive niches in colorectal cancer. [Journal Article]
- CONCLUSIONS: This study uncovered previously unrecognized immunosuppressive cell populations and key immune regulators that advance understanding of CRC immune evasion and highlight potential targets for personalized immunotherapy.
- Publisher Full Text (DOI)
- Clinical significance of circulating macrophage markers across different stages of prostate cancer: highlighting soluble CD163. [Journal Article]
- CONCLUSIONS: Circulating levels of sCD163 and sSIRPα were increased in patients with metastatic compared to localised PC. Further, higher sCD163 levels predicted worse PFS in mCRPC, suggesting potential as a future minimally-invasive biomarker to aid mCRPC prognostication.
- Publisher Full Text (DOI)
- Abundant CD8[+] tumor-infiltrating lymphocytes in glioblastoma harbor distinct exhaustion signatures in potentially reactive subsets. [Journal Article]
- CONCLUSIONS: TILs with marked clonal expansion in certain GBM cases may include potentially reactive T cells with distinct exhaustion features, providing a foundation for the development of antigen-specific and LAG-3-targeted immunotherapies.
- Publisher Full Text (DOI)
- From initial complete response to recurrence: ENPP1 mutation drives cisplatin resistance through STING/NF-κB/IL-6 axis in hypopharyngeal squamous cell carcinoma. [Journal Article]
- CONCLUSIONS: Our study identifies ENPP1 mutation as one of the key genetic drivers of recurrence, mediating both chemotherapy resistance and immunomodulation.
- Publisher Full Text (DOI)
- Switches in alternatively spliced isoforms impact protein and drug interactions in melanoma, ovarian cancer, and acute myeloid leukemia. [Journal Article]
- CONCLUSIONS: This study identifies cMDTs that may serve as candidate biomarkers in melanoma, ovarian cancer, and AML, with the potential to improve cancer diagnosis and support clinical decision-making.
- Publisher Full Text (DOI)
- Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer. [Journal Article]Br J Cancer. 2026 Sep 30. [Online ahead of print]BJ
- CONCLUSIONS: In PARPi-naïve patients with BRCA1/2 m HER2-negative breast cancer, ceralasertib-olaparib had generally manageable safety and demonstrated preliminary antitumour activity.
- Publisher Full Text (DOI)
- A prospective observational study of treatment sequencing with regorafenib and FTD/TPI in metastatic colorectal cancer: The OSERO study. [Journal Article]
- CONCLUSIONS: Sequential treatment with REGO and FTD/TPI plus BEV therapy yielded comparable survival, suggesting that treatment selection may depend on safety profiles of each drug.
- Publisher Full Text (DOI)
- Neoadjuvant chemotherapy as a bridge to surgery versus direct surgery following SEMS placement in obstructive left-sided colon cancer: a multicenter prospective cohort study. [Journal Article]
- CONCLUSIONS: The SEMS-neoadjuvant-surgery strategy is associated with superior long-term survival without increasing SEMS-related complications, strongly supporting its clinical feasibility and oncological safety for COLCC.
- Publisher Full Text (DOI)
- VISTA drives tumour-intrinsic proliferation in mesothelioma cells. [Journal Article]
- CONCLUSIONS: These findings indicate that VISTA promotes mesothelioma cell proliferation through tumour-intrinsic signalling independent of immune modulation. VISTA is a promising subtype-specific therapeutic target for mesothelioma.
- Publisher Full Text (DOI)
- A plasma derived hypoxia signature predicts benefit from hypoxia-modifying radiotherapy and reveals dynamic humoral immune modulation in bladder cancer. [Journal Article]
- CONCLUSIONS: These findings support the use of low abundance plasma biomarkers for real-time hypoxia stratification, revealing dynamic immune responses during radiotherapy associated with hypoxia.
- Publisher Full Text (DOI)
- Small extracellular vesicles from the plasma of head and neck cancer patients induce dysfunctional T cell phenotypes. [Journal Article]
- CONCLUSIONS: Our findings suggest that plasma sEVs contribute to systemic immune modulation in HNC by inducing dysfunctional T-cell phenotypes. The ability of plasma-derived sEVs to modulate IC expression on T cells underscores the need for further investigation into their relevance for immunotherapeutic strategies in HNC.
- Publisher Full Text (DOI)